logologo

Popular Boards

Primary Link Pubmed DOI Openalex Full text (OA)

Key Takeaways

Sample Definition And Size

The study is a retrospective multicenter cohort study including 1,604 patients with stage II colorectal cancer (CRC), represented by 6,950 H&E-stained whole-slide images (WSIs). The cohorts comprised: Internal‑CRCII (743 patients, 3,494 slides), External‑CRCII‑1 (352 patients, 1,315 slides), External‑CRCII‑2 (331 patients, 1,708 slides), and TCGA‑CRCII (178 patients, 433 slides) ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)).

Study Type

Retrospective multicenter cohort study employing deep learning (SurvFinder framework) with multiple-instance learning, segmentation networks, multi-view fusion (MVNet), and multimodal fusion (MMF) integrating histopathological image features and clinical data ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)).

Conflicts Of Interest

The authors declared that no competing interests exist ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)).

Results Summary

Key findings: SurvFinder identified tertiary lymphoid structures (TLSs) as critical prognostic features. MVNet (multi-view fusion of spatial and morphological TLS features) achieved AUROCs of 0.827 (95% CI 0.789–0.864), 0.805 (95% CI 0.749–0.860), and 0.805 (95% CI 0.748–0.861) across Internal‑CRCII, External‑CRCII‑1, and External‑CRCII‑2 cohorts, respectively, outperforming WSINet and single-branch models ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)). In multivariate Cox regression, MVNet had a hazard ratio (HR) of 8.23 (95% CI 5.43–12.47; p < 0.001), indicating strong independent prognostic value ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)). The MMF model combining MVNet with clinical variables further improved AUROC compared to MVNet or clinical-only models ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)). In high-risk patients as predicted by MVNet, adjuvant chemotherapy (ACT) was associated with significantly improved relapse-free survival in Internal‑CRCII (p = 0.023), External‑CRCII‑1 (p = 0.026), and External‑CRCII‑2 (p = 0.00081) cohorts; low-risk patients did not benefit from ACT ([journals.plos.org](https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1004614)).

Abstract

Together, these results highlight the potential utility of deep learning-based histopathological analysis for automated risk stratification in stage II CRC. In particular, our findings support the relevance of TLSs as a histological biomarker with potential implications for personalizing ACT decisions.

Referenced In

Mercedes C.
2 months ago
AI Papers and Discussion

Colorectal Cancer (CRC) is the 3rd most common cancer worldwide 🌍 , accounting for approximately 10% of all cancer cases.

According to world health organisation (WHO) - in 2022, an estimated 1.9 million new cases of colorectal cancer and more than 900 000 deaths 💀 occurred worldwide.

With the wave of AI-powered innovations transforming how we predict patient outcomes, stratify risk, and personalise treatment: Here are THREE landmark studies from 2025-2026, targeting colorectal cancer.

🔬 SurvFinder: Deep Learning Discovers Novel Prognostic Biomarkers

The Innovation: Researchers built a multi-view deep learning system that analyzes routine H&E slides from multiple angles to identify something pathologists rarely assess systematically: tertiary lymphoid structures (TLSs). These organised immune cell clusters form in response to tumours, and their location and maturity strongly predict outcomes.

The Achievement:

  • 6,950 slides from 1,604 patients across 4 independent cohorts

  • AUROC of 0.827 for predicting recurrence risk

  • High-risk patients showed 8.23× higher hazard for relapse than low-risk

Why It Matters: SurvFinder discovered a clinically actionable biomarker hidden in ordinary microscope slides of tumour tissue. In a disease where 20% relapse post-surgery, this system allows for better treatment plans.

🩸 ColoLDB: Making Precision Medicine Accessible

The Innovation: This is a machine learning model that uses only standard laboratory parameters — complete blood counts, liver function tests, inflammatory markers, and basic metabolic panels — to predict CRC risk and outcomes.

The Achievement:

  • Uses XGBoost and ensemble methods for robust predictions

  • Requires no specialized equipment beyond existing lab infrastructure, which enables population-level screening in resource-limited settings

  • Demonstrated comparable performance to more complex multi-modal systems in specific prediction tasks

Why It Matters: While digital pathology AI grabs headlines, ColoLDB addresses global health equity. By leveraging existing lab infrastructure, it brings AI-powered risk prediction to low-resource settings where CRC mortality remains highest.

🧬 HIBRID: When Two Tests Become One Smart Prediction

The Innovation: First system to combine AI analysis of microscope slides with circulating tumour DNA (ctDNA) blood tests — fusing analysis on how the tumour looks like and whether tumour DNA remains in the body.

The Achievement:

  • Tested on 1,023 stage II patients and Identified four distinct risk strata enabling nuanced treatment decisions

  • Found patients with scary-looking tumours but clean blood tests still face 18% recurrence risk

  • Found patients with benign-looking tumours but positive blood tests face 31% recurrence risk

Why It Matters: HIBRID establishes multi-modal AI as clinically viable, not experimental. It transforms binary treatment decisions into probabilistic, personalised medicine — sparing low-risk patients chemotherapy toxicity while ensuring high-risk patients receive intervention.

Read Full Post
3